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Abstract
AIM
To evaluate brain involvement in quiescent Crohn’s 
disease (CD) patients with fatigue using quantitative 
magnetic resonance imaging (MRI).
METHODS
Multiple MRI techniques were used to assess cerebral 
changes in 20 quiescent CD patients with fatigue 
(defined with at least 6 points out of an 11-point 
numeric rating scale compared with 17 healthy age and 
gender matched controls without fatigue. Furthermore, 
mental status was assessed by cognitive functioning, 
based on the neuropsychological inventory including 
the different domains global cognitive functioning, 
memory and executive functioning and in addition 
mood and quality of life scores. Cognitive functioning 
and mood status were correlated with MRI findings in 
the both study groups.
RESULTS
Reduced glutamate + glutamine (Glx = Glu + Gln) 
concentrations (P  = 0.02) and ratios to total creatine 
(P  = 0.02) were found in CD patients compared with 
controls. Significant increased Cerebral Blood Flow 
(P  = 0.05) was found in CD patients (53.08 ± 6.14 
mL/100 g/min) compared with controls (47.60 ± 8.62 
mL/100 g/min). CD patients encountered significantly 
more depressive symptoms (P  < 0.001). Cognitive 
functioning scores related to memory (P  = 0.007) 
and executive functioning (P  = 0.02) were lower in 
CD patients and both scores showed correlation with 
depression and anxiety. No correlation was found 
subcortical volumes between CD patients and controls 
in the T1-weighted analysis. In addition, no correlation 
was found between mental status and MRI findings.
CONCLUSION
This work shows evidence for perfusion, neurochemical 
and mental differences in the brain of CD patients with 
fatigue compared with healthy controls.
Key words: Magnetic resonance imaging; Systemic 
inflammation; Fatigue; Crohn’s disease; Cognition
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: The present study explores perfusion, neuro-
chemical and mental differences in the brain of Crohn’s 
disease (CD) patients compared with healthy controls. 
This implies that for a gastroenterologist it is important 
to focus, besides gastrointestinal symptoms due to 
inflammation, on the effects of systemic inflammation 
on the brain and mental status. Knowledge and 
understanding of these effects in CD patients may help 
health professionals to set up interventions to maintain 
CD remission and improve mental status by e.g.  psycho-
social interventions.
Van Erp S, Ercan E, Breedveld P, Brakenhoff L, Ghariq E, 
Schmid S, van Osch M, van Buchem M, Emmer B, van der 
Grond J, Wolterbeek R, Hommes D, Fidder H, van der Wee 
N, Huizinga T, van der Heijde D, Middelkoop H, Ronen I, van 
der Meulen-de Jong A. Cerebral magnetic resonance imaging 
in quiescent Crohn’s disease patients with fatigue. World J 
Gastroenterol 2017; 23(6): 1018-1029  Available from: URL: 
http://www.wjgnet.com/1007-9327/full/v23/i6/1018.htm  DOI: 
http://dx.doi.org/10.3748/wjg.v23.i6.1018
INTRODUCTION
Crohn’s disease (CD) is a relapsing inflammatory bowel 
disease (IBD)[1], characterized by segmental transmural 
lesions that can affect any part of the gastrointestinal 
tract[2]. Besides gastrointestinal symptoms, fatigue is 
common in CD patients. In contrast to regular fatigue 
which affects nearly everyone, disease-related fatigue 
is more long lasting and may occur despite sufficient 
sleep and rest. Generally, fatigue lasting for more than 
6 mo is considered chronic and is significantly more 
prevalent in IBD patients than in healthy controls[3]. 
Although fatigue is influenced by IBD disease activity, 
40% of the patients with quiescent disease report 
fatigue as well and contributes negatively to the 
patients’ health-related quality of life (QoL)[4,5].
The pathogenesis of CD is multifactorial and results 
from an impaired interaction between environment, 
commensal microbiota and the human immune 
system, leading to a chronic inflammatory status and 
eventually CD[6,7]. Furthermore, in both quiescent 
and active CD patients increased levels of circulating 
inflammatory cytokines, such as tumour necrosis 
factor-α (TNF-α) are reported[8-10]. Although quiescent 
CD patients report fewer clinical symptoms and score 
less on the clinical activity score compared with active 
CD patients, inflammatory cytokines are present[9,10]. 
TNF-α can be secreted by a large variety of cells[8] 
and can initiate a signalling stimulus to the brain 
parenchyma that will subsequently activate microglia. 
Activated microglia stimulates the production of 
monocyte chemo-attractant protein (MCP)-/CCP2, 
which recruits monocytes into the brain[9-11]. Moreover, 
this cerebral infiltration of monocytes plays an impor-
tant role in driving inflammation in the brain[11-13].
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Magnetic resonance imaging (MRI) is an imaging 
technique widely used to visualize the effect of several 
neurological diseases, such as Multiple Sclerosis (MS), 
Parkinson’s Disease and Alzheimer disease, in the 
brain[14]. A variety of MRI methods can be employed 
to identify cerebral changes due to a specific disease. 
These methods include T1-weighted imaging, mag-
netization transfer imaging (MTI), magnetic reso-
nance spectroscopy (MRS), arterial spin labeling (ASL) 
and diffusion tensor imaging (DTI). T1-weighted ima-
ging provides high-resolution, high-contrast anatomi-
cal images of the brain and can be used to determine 
the volumes of the grey matter (GM), white matter 
(WM), cerebral spinal fluid (CSF) and subcortical struc-
tures[15]. Through voxel based morphometry (VBM), it 
is possible to visualize local changes in GM volumes[16]. 
MTI is a technique sensitive to brain tissue micro-
structural changes, stemming from changes in macro-
molecules such as myelin or cell membranes[17]. MRS 
measures the concentration of certain metabolites in 
living tissues and gives evidence for neurochemical 
changes[18]. ASL is a non-invasive tool for the quan-
tification of regional cerebral blood flow (CBF)[19] and 
can reveal changes in tissue perfusion. DTI is sensi-
tive to minute changes in tissue microstructure, such 
as changes in myelin integrity and axonal density in 
white matter fiber tracts, based on the random motion 
or diffusion of water molecules[20].
Previous MRI studies have shown that systemic 
inflammation contributes to cognitive decline, for 
example in relation to aging[21], but also to brain 
diseases including Alzheimer disease, MS and 
Parkinson’s disease by promoting activation of the 
immune system[22-24]. Metabolic and cerebral perfusion 
changes have been found in the brain of patients with 
Rheumatoid Arthritis (RA), Systemic Sclerosis and 
Systemic Lupus Erythematosus (SLE)[11,12,25-31]. In 
addition, previous studies performed in patients with 
Chronic Fatigue Syndrome (CFS) found an association 
between fatigue complaints and metabolic changes in 
the brain as well[32-34]. In CFS patients, the mean ratio 
of choline (Cho) to creatine (Cr) in the occipital cortex 
was significantly higher than in controls, indicating an 
abnormality of phospholipid metabolism in the brain 
in CFS[32-33]. These findings suggest that systemic 
inflammation and fatigue complaints could have 
structural, neurochemical and functional correlates in 
the brain. So far, the link between systemic inflamma-
tion, disease-induced fatigue and changes in the brain 
have not been explored in CD patients. The aim of this 
exploratory study was to investigate to what extent 
systemic inflammation affects the brain of quiescent 
CD patients, by using a variety of MRI acquisition 
methods and neuropsychological examinations that 
assess cognition, mood and QoL. Furthermore, the 
correlation between MRI changes, clinical character-
istics, including fatigue scores, and mental status was 
investigated.
MATERIALS AND METHODS
Study population and study design
In this case-control study 20 CD patients and 17 age 
and gender matched healthy controls were included. 
Since it is known from literature that there is an age 
associated decrease in brain volume, primarily caused 
by a decrease in neuronal size and partly due to a 
reduction in numbers of neurons caused by apop-
tosis[35], a correction was made for this confounder by 
matching the subjects.
Consecutive CD patients, fulfilling the inclusion cri-
teria, were recruited through the IBD outpatient clinic 
of the department of Gastroenterology and Hepatology 
of the Leiden University Medical Center (LUMC), the 
Netherlands. The patients had endoscopic proven 
CD for at least 3 mo before inclusion, were in clinical 
remission and experienced fatigue. CD patients with 
anemia (Hb < 7.0 mmol/L), primary sclerosing cholan-
gitis and routine MRI-contraindications (e.g., instable 
metal implants or a pacemaker) were excluded. All 
medication deemed necessary by the gastroenterolo-
gist was allowed at study inclusion, except for anti-
TNFα or corticosteroid use, since this medication could 
reduce systemic inflammation the most and thus 
influence clinical disease activity. Healthy controls 
were recruited via an advertisement in het LUMC and 
included in the study if they had no anamnestic brain 
abnormalities, nervous system disease or chronic 
inflammation in the body. A 1-d program was set up 
for all participants by the relevant medical specialists, 
including a gastroenterologist, radiologist, psychiatrist 
and neuropsychologist and all individuals were asked 
to complete several questionnaires at study inclusion 
about demographics, mental status and QoL. This 
study was approved by the institutional medical ethical 
committee of the LUMC and all patients signed a writ-
ten informed consent prior to study enrolment.
Clinical characteristics
Disease activity: The clinical disease activity of the 
CD patients was measured with the Harvey-Bradshaw 
Index (HBI). The HBI consists of 12 criteria, which 
include general well-being, abdominal pain, daily 
number of liquid stools, abdominal mass and extra 
intestinal manifestations (arthralgia, uveitis, erythema 
nodosum, aphthous ulcers, pyoderma gangrenosum, 
anal fissure, new fistula and abscess). Patients with 
an HBI score of 4 or less were classified as having 
quiescent CD disease[36].
Fatigue: Fatigue was assessed with the Multidimen-
sional Fatigue Index (MFI) and the Visual Analogue 
Scale (VAS). The MFI is a self-report measurement 
containing 20 questions consisting of 5 subscales 
covering different dimensions: general fatigue, physical 
fatigue, mental fatigue, reduced activity and reduced 
motivation. The questions are about the fatigue experi-
enced by the subject in the 7 d prior to examination. 
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Scores range from 4 to 20, with higher scores indicat-
ing higher levels of fatigue[37]. The VAS consists of a 
10 point self-rating scale that measures subjective 
experiences of fatigue. The participants had to indicate 
on a visual line how they were currently feeling. Six 
points or more indicated the presence and experience 
of fatigue in individuals[38].
MRI data acquisition
All study subjects underwent MRI of the brain, using a 
Philips Ingenia 3.0 Tesla MRI Scanner (Philips Medical 
Systems, Best, The Netherlands) equipped with a 12 
channel head coil, and images were evaluated by an 
experienced neuroradiologist (MvB). The MRI protocol 
consisted of T1-weighted imaging, MTI, MRS, ASL 
and DTI, and lasted for about 60 min. Since more CD 
patients were included and all patients and healthy 
controls were age-gender matched, in total 3 CD 
patients, who matched the least with the controls, 
got excluded from the voxel-based analysis of the 
T1-weighted and DTI data. For the MRS and ASL 
analyses data of some CD subjects were either miss-
ing because of time limitations or excluded due to low 
quality, caused by subject motion. For the MRS analy-
sis only 9 CD patients and 9 age and gender matched 
controls were included, and for the ASL analysis 16 
CD patients and 16 age and gender matched controls 
were included (Figure 1). The MRI scan protocol con-
sisted of (1) axial 3D T1-weighted images (FOV: 224 
mm × 144 mm × 182 mm, resolution: 0.88 mm × 0.88 
mm × 1.20 mm, TR/TE = 9.75/4.59 ms); (2) sagittal 
FLAIR images (FOV: 224 mm × 144 mm × 180 mm, 
resolution: 0.5 mm × 0.5 mm × 3.6 mm, TR/TE/TI = 
10000/120/1650 ms); (3) axial DTI (FOV: 176 mm × 
144 mm × 224 mm, resolution: 1.75 mm × 1.75 mm 
× 3.6 mm, TR/TE = 4317/55.33 ms, one volume with 
b = 0 s/mm2 and 32 diffusion-weighted volumes with 
b = 800 s/mm2 ); (4) axial MTI (FOV: 224 × 144 × 
180, resolution: 0.88 mm × 0.88 mm × 7.2 mm, TR/
TE = 100/10.95 ms, two volumes acquired one with 
and one without a radiofrequency saturation pulse); (5) 
ASL (FOV: 240 mm × 240 mm × 133 mm, resolution: 
3.0 mm × 3.0 mm × 7.0 mm, TR/TE = 4000/15.19 
ms, labeling duration = 1650 ms, post-labeling delay 
= 1525 ms, 35 label and control pairs and background 
1021 February 14, 2017|Volume 23|Issue 6|WJG|www.wjgnet.com
suppression inversion pulses at 50 and 1150 ms); and 
(6) a single volume, stimulated echo acquisition mode 
(STEAM) 1H MRS scan with a volume of interest (VOI) 
located in the left centrum semi ovale, containing 
mostly white matter as shown in Figure 2 (voxel size 
= 30 mm × 15 mm × 15 mm, TR/TE = 2000/14 ms, 
mixing time = 19 ms, sample size = 2048, number of 
averages = 96).
Post-processing and data analysis
T1-weighted image analysis: Brain extraction tool 
(BET) of FMRIB Software Library (FSL) (http://www.
fmrib.ox.ac.uk/fsl) was used to extract the brain 
tissue from T1-weighted images[15]. FSL FMRIB’s 
Automated Segmentation Tool (FAST)[39] was used 
to segment GM, WM and CSF tissues from the brain 
extracted T1-weighted images. FSL FMRIB’s Integrated 
Registration and Segmentation Tool was used to 
segment subcortical structures: nucleus accumbens, 
amygdala, caudate, hippocampus, globus pallidus, 
putamen and thalamus[40]. Following segmentation, 
the volumes of GM, WM and subcortical structures 
were calculated using FSL Maths. The volumes were 
normalized to subject intracranial volume by dividing 
the volumes with the total brain volume of the same 
subject. VBM in FSL was used to assess local GM dif-
ferences between CD patients and controls[16,41].
MTI analysis: MTI were split into images with and 
without saturation. Both images, with and without 
saturation, were brain extracted with BET and the 
image without saturation was aligned to the image 
with saturation. After alignment, the magnetization 
transfer ratio (MTR) of the whole brain was calcu-
lated using FSL Maths. The MTR images were then 
registered to the T1-weighted images from the same 
subject with FLIRT[42]. Subsequently, MTR images were 
multiplied with the binary GM and WM masks from 
the same subject, to create GM and WM MTR images. 
Tissue-specific histograms of MTR values from the GM 
and WM of patients and controls were created using 
an in house-developed MATLAB® program (Mathworks, 
Natick, MA, United States).
MRS analysis: The MRS analysis was performed 
Figure 1  Flowchart of included participants in the magnetic resonance imaging analyses. CD: Crohn’s disease; VBM: Voxel based morphometry; MTI: 
Magnetization transfer images; MRS: Magnetic resonance spectroscopy; ASL: Arterial spin labelling; DTI: Diffusion tensor imaging.
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in MATLAB and LCmodel[43]. An in-house developed 
MATLAB code was used to calculate and correct for 
GM, WM and CSF tissue fraction (%) within the VOI 
for each subject separately. LCmodel was used for 
the calculation of the concentration and ratio to total 
creatine (tCr) of the metabolites N-acetyl-aspartate 
(NAA), creatine (Cr), glutamate (Glu), myo-inositol 
(Ins), glutamine (Gln), N-acetyl-aspartyl-glutamate 
(NAAG) and choline (Cho). Institutional units (IU) of 
concentration were expressed in mmol. Among these 
metabolites, NAA is a neuronal marker, NAAG is sug-
gested to be related to excitatory neurotransmission, 
total Creatine (tCr), the sum of phosphocreatine and 
creatine, is a marker of energy metabolism. Cho is 
related to cell membrane turnover, Glu is an excitatory 
neurotransmitter predominantly found in neurons, Gln 
is a precursor for Glu and found mostly in astrocytes, 
and Ins is a possible astrocytic marker[44]. The mean 
ratios of NAA, Glu, Ins, Gln, NAAG and Cho to tCr were 
compared between the two study groups.
ASL analysis: The average GM Cerebral Blood 
Flow value was calculated in FSL[45]. The ASL label 
and control images were motion corrected by FSL 
MCFLIRT[46]. The perfusion maps were calculated for 
each subject by subtracting the label from the control 
images and averaging those images. Following that, 
perfusion maps from each subject were registered 
first linearly and then nonlinearly to GM volume seg-
mented from the T1-weighted image of the subject 
and subsequently they were first linearly and then 
nonlinearly registered to average brain template from 
the Montreal Neurological Institute (MNI). CBF of the 
GM is calculated by using a binary GM mask of the 
subject with a threshold of 60% GM probability and 
using the following equation:
Where λ is the blood/brain partition coefficient in 
mL/g which was 0.9, ΔM is the signal intensity of the 
control image subtracted with the signal intensity of 
the label image, the post labelling delay was 1525 
ms. T1a is the longitudinal relaxation time of the blood 
was 1664 ms, SIPD is the signal intensity of a proton 
density-weighted image and τ is the label duration 
which was 1650 ms. ΑpCASL is the labelling efficiency, 
which was 0.85 and αBSup was 0.83. A comparison of 
GM CBF was made between the patients and controls.
Diffusion tension images analysis: ExploreDTI soft-
ware[47] was used for motion and distortion correction 
of the DTI images and for calculating the Fractional 
Anisotropy (FA) and Mean Diffusivity (MD) maps. FA 
and MD maps were used as an input to tract-based 
spatial statistics processing[48], which was carried out in 
FSL. The FA maps were first linearly registered with an 
affine transformation, subsequently non-linearly reg-
istered to the MNI space, and a mean FA skeleton was 
created. For each subject, the FA map was projected 
on the skeleton. Following that, randomisation was 
used to perform t-test based voxel-wise comparison of 
the FA skeletons between patients and controls. The 
same procedure was repeated for MD maps.
Assessment of cognitive performance
Cognition: Several neuropsychological assessments 
were conducted in both healthy controls and CD 
patients and evaluated by an experienced clinical 
neuropsychologist (HM). The examination took approxi-
mately one hour and included validated test methods in 
a fixed order. Since the cognitive functioning of patients 
with IBD has not been fully previously investigated, the 
focus was on a wide range of neuropsychological func-
tions. Global cognitive functioning was assessed by the 
Minimal Mental State Examination (MMSE). The MMSE 
contained 11 questions, subdivided into 5 subdomains. 
All questions were scored individually and added to 
produce a total score ranging from 0 to 30, with higher 
scores indicating better cognitive functioning[49]. The 
memory domain was evaluated with the Digit Span 
Forward and Backward subtests of, respectively the 
revised Wechsler Adult Intelligence Scale (WAIS-R)[50] 
and the revised Wechsler Memory Scale (WMS-R). 
Higher scores reflected better memory performance[51]. 
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Figure 2  Planning of the 1H-magnetic resonance spectroscopy volume of interest in the left centrum semi-ovale. Seen on axial (left) and on the coronal (right) 
T1-weighted image slices. The effective volume of interest set at the tNAA frequency is shown (red rectangle) together with the shimming volume (yellow rectangle). 
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Executive functioning was assessed by the Word 
Fluency Test (WFT)[52], Stroop-Color-Word test 
(SCWT)[53] given in three parts, and the Trail Making 
Test (TMT)[54] subdivided into two parts, whereby part A 
measured attention and performance speed, and part 
B measured mental flexibility and ability to shift atten-
tion. The TMT involved scanning, visuomotor tracking, 
divided attention and cognitive flexibility. The time used 
for each trial was noted, with more time used indicating 
lower performance. The SCWT was used to measure 
interference sensibility. One response (reading the 
word) should be inhibited in order to name the colour 
of the ink, which leads to a delay in reaction time. The 
number of correct responses within 45 seconds was 
counted[53]. Furthermore, the WAIS-R Digit symbol and 
Digit cancellation test was measured[50].
Mental status: Cognitive performance depends on 
the psychiatric status of the patient[55], and therefore 
the Hospital Anxiety Depression Scale (HADS) was 
included in the neuropsychological examination. The 
HADS was used to determine depressive symptoms 
and anxiety. HADS is a widely used measurement 
to identify emotional disorders in non-psychiatric 
patients. The scale includes 14 items, 7 items concer-
ning anxiety and 7 concerning depression, each scored 
between 0 and 3. A score above 8 on each individual 
scale were considered as a possible case and a score 
above 10 as a probable case[56].
QoL: To determine the QoL, the Short Form-36 (SF-36) 
was used. The SF-36 is a generic questionnaire to 
assess self-reported QoL. This measurement includes 
in total 8 subscales covering physical and mental 
aspects of QoL. The score ranges from 0 to 100, with 
higher score indicating better QoL. The Dutch transla-
tion of the SF-36 was validated in both the general 
population and in CD patients[57].
Statistical analysis
Data analyses were performed using SPSS 20.0, IBM 
Corp, 2011, Armonk, NY, United States. Descriptive 
statistics were used for the patients’ characteristics. All 
comparisons between the patient and control groups 
were performed with an independent t-test. A P-value 
≤ 0.05 was considered statistically significant. To cor-
rect for multiple testing, the level of significance was 
set at P < 0.01 (0.05/5) and P < 0.006 (0.05/8) for 
the fatigue (five MFI subscores) and QoL (eight SF-38 
subscales) scores, respectively. Based on the individual 
cognitive tests corrected for education, Z-scores of 
the different cognitive domains were created by using 
the UNIANOVA test with an average mean ± SD. 
Correlations between the MRI outcomes, cognition 




In this study, 20 CD patients and 17 healthy controls 
were age (P = 0.46) and gender matched (P = 0.68). 
All patients were in clinical remission at study inclusion 
(mean HBI = 2.16, SD = 1.12), with an average age 
of onset at 21.4 years and an IBD disease duration 
of 8.8 years. Based on the inclusion criteria, patients 
reported more fatigue complaints according to the 
MFI-20 (P < 0.001) and VAS fatigue score (P < 0.001) 
compared with the control subjects. Furthermore, the 
education level of the healthy controls was significantly 
higher than that of the CD patients. Since this variable 
might influence mental status scores, a correction was 
made. An overview of the clinical characteristics of the 
individuals is presented in Table 1.
MRI analysis
Volumetric data: The comparison of the subcortical 
volumes between the CD patients and controls in 
the analysis of the T1 weighted images did not show 
significant differences between the two subject groups. 
The volume differences in the right amygdala (P = 
0.08) and nucleus accumbens (P = 0.08) just missed 
significance (Table 2). VBM analysis showed a lower 
GM content in the superior frontal gyrus in CD patients 
compared with healthy controls (P < 0.05) (Figure 3). 
MTI data: No significant differences were observed in 
the mean MTR values or in the MTR histogram peak 
heights of the CD patients compared with healthy 
controls. 
MRS data: Lower glutamate + glutamine (Glx = Glu 
+ Gln) concentrations (4.85 ± 0.78 mmol vs 5.96 ± 
0.98 mmol, P = 0.02) and ratios to tCr (0.92 ± 0.13 
vs 1.10 ± 0.14, P = 0.02) were found in the patient 
population compared with control subjects (Table 3).
ASL data: Average GM CBF of the CD patients (53.1 
± 6.1 mL/100 g/min) was significantly higher than 
the GM CBF of the control group (47.6 ± 8.6 mL/100 
g/min) (P = 0.05).
DTI data: No differences were observed across white 
matter in the FA and MD values between CD patients 
and controls.
Mental status
Neuropsychological examination and cognitive scores 
were corrected for educational level (Table 4). 
Generally, a difference close to significance between 
patients and controls was found in several individual 
cognitive test scores. Compared with controls, CD 
patients had a lower Stroop interference index (P 
= 0.06), a reduced total score of the WAIS-R Digit 
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Symbol test (P = 0.06) and were slower in completing 
trial A of the TMT test (P = 0.08). When the individual 
tests were transformed into a Z-score based on the dif-
ferent cognitive domains, significant reduced Z-scores 
of the memory domain (P = 0.007) and executive 
functioning domain (P = 0.02) were found in the 
patient population compared with the healthy controls 
(Table 5). CD patients experienced more depressive 
symptoms (P < 0.001), were more anxious (P = 0.002) 
and reported a significantly lower QoL.
Correlation of MRI findings with clinical characteristics 
and mental status
No correlations were found between mental status, 
including depression and anxiety, and MRI findings. 
Depressive symptoms were correlated with reduced 
scores of global cognitive functioning (r = -0.5, P = 
0.003), memory (r = -0.34, P = 0.04) and executive 
functioning (r = 0.35, P = 0.04). Additionally, CD 
patients reported in the present study increased symp-
toms of anxiety and this was significantly correlated 
with reduced global cognitive functioning (r = -0.36, P 
= 0.03) and memory scores (r = -0.32, P = 0.05). No 
further correlations between cognitive scores, disease 
activity, disease duration and MRI findings were found 
in this study.
DISCUSSION
Several MRI techniques were used in this study in a 
cross-sectional manner to examine the differences 
in brain morphology, neurochemistry and perfusion 
between CD patients with fatigue and healthy controls 
without fatigue. The most important findings reported 
in this study are the significant differences in perfusion, 
neurochemistry and mental status (e.g., cognition, 
mood and QoL) between patients and controls. Lower 
levels of Glx concentration and their ratio to tCr were 
observed and an increased CBF was found in the 
patient population compared with control subjects. CD 
patients scored lower on several individual cognitive 
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Table 2  Group mean subcortical structure volumes as 
percentage of the total brain volume in Crohn’s disease 
patients and controls 
CD patients
(n  = 20)
Controls
(n  = 17)
P value
Left Accumbens 0.04 ± 0.01 0.04 ± 0.01 0.56
Left Amygdala 0.09 ± 0.01 0.09 ± 0.01 0.61
Left Caudate 0.24 ± 0.02 0.24 ± 0.02 0.94
Left Hippocampus 0.27 ± 0.02 0.27 ± 0.03 0.94
Left Pallidus 0.13 ± 0.01 0.12 ± 0.01 0.32
Left Putamen 0.33 ± 0.02 0.32 ± 0.03 0.24
Left Thalamus 0.54 ± 0.02 0.54 ± 0.03 0.94
Right Accumbens 0.04 ± 0.00 0.03 ± 0.01 0.08
Right Amygdala 0.08 ± 0.01 0.09 ± 0.01 0.08
Right Caudate 0.25 ± 0.03 0.25 ± 0.02 0.76
Right Hippocampus 0.26 ± 0.02 0.27 ± 0.03 0.22
Right Pallidus 0.12 ± 0.01 0.13 ± 0.01 0.30
Right Putamen 0.31 ± 0.08 0.32 ± 0.02 0.56
Right Thalamus 0.53 ± 0.02 0.52 ± 0.03 0.48
Mean in % ± SD. CD: Crohn’s disease.
Table 1  Demographic characteristics
CD patients 
(n  = 20)
Controls 
(n  = 17)
P  value
Age (yr) at inclusion, mean ± SD 30.1 ± 6.2 28.5 (6.7)    0.460
Female, n (%) 17 (85.0) 13 (76.5)    0.680
HBI score, mean ± SD1   2.2 ± 1.1 - -
Age of IBD onset (yr), mean ± SD 21.4 ± 5.7 - -
IBD disease duration (yr), mean ± SD   8.8 ± 7.2 - -
Smoker, n (%) 11 (55.0)   4.0 (23.5)    0.400
VAS, mean ± SD 7.4 (1.3) 3.4 (2.3) < 0.001
MFI, mean ± SD 66.1 (13.3) 36.4 (10.3) < 0.001
General Fatigue 16.4 (2.8) 8.9 (3.3) < 0.001
Physical Fatigue 14.4 (3.0) 6.2 (2.2) < 0.001
Mental Fatigue 12.8 (4.1) 7.2 (2.9) < 0.001
Reduced Activity 10.7 (3.5) 6.9 (2.7) < 0.001
Reduced Motivation 12.0 (3.6) 7.1 (2.7) < 0.001
Education level, n (%)    0.001
Lowa   4 (20) -
Intermediateb 10 (50) 2 (11.8)
Highc   6 (30) 15 (88.2)
Montreal classification
Location CD, n (%)
L1 ileal      3 (15.0) - -
L2 colonic      2 (10.0) - -
L3 ileocolonic    15 (75.0) - -
L4 upper - - -
L1-3 + L4 - - -
Behaviour CD, n (%)
B1 non-stricturing/penetrating    15 (75.0) - -
B2 stricturing      3 (15.0) - -
B3 penetrating      2 (10.0) - -
+ Perianal disease      3 (15.0) - -
Medication use, n (%)
Immunosuppressive drugs 
(Aza/6MP)
   12 (60.0) - -
None      8 (40.0) - -
1HBI missing of 1 Crohn’s disease (CD) patient. aLow: primary education 
(elementary school) and lower secondary education (preparatory 
secondary education); bIntermediate: higher secondary education (higher 
general continued education, pre-university secondary education) and 
postsecondary education (intermediate vocational education); cHigh: 
tertiary education (higher professional education, university). To correct 
for multiple testing, the level of significance was set at P < 0.01 for the MFI 
score. HBI: Harvey Bradshaw Index; VAS: Visual Analogue Scale; MFI: 
Multidimensional fatigue index.
Table 3  Mean metabolite ratio to total creatine
CD patients
(n  = 9)
Controls
(n  = 9)
P  value
Ratio Glu:tCr 0.76 ± 0.12 0.84 ± 0.10 0.19
Ratio Cho:tCr 0.29 ± 0.02 0.29 ± 0.04 0.81
Ratio Ins:tCr 0.66 ± 0.08 0.70 ± 0.10 0.38
Ratio NAA:tCr 1.31 ± 0.12 1.27 ± 0.09 0.44
Ratio NAA + NAAG:tCr 1.59 ± 0.18 1.56 ± 0.13 0.69
Ratio Glu + Gln:tCr 0.92 ± 0.13 1.10 ± 0.14 0.02
Mean metabolite ratio to tCr in mmol ± SD. CD: Crohn’s disease; tCr: 
Total Creatine; Glu: Glutamate; Cho: Choline; Ins: Insulin; NAA: N-Acetyl 
Aspartate; NAAG: N-Acetyl Aspartate Glutamate; Gln: Glutamine.
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test scores, with a trend towards significance, and 
scored significantly lower on the memory and the 
executive functioning domain compared with the 
healthy controls. Also, the patient population had a 
significantly lower QoL and mood status.
The present study observed with MRS a signifi-
cantly reduced Glx concentration as well as a lower 
ratio of Glx to tCr in the CD group. Glutamate is the 
predominant excitatory neurotransmitter in the brain 
and is involved in different brain functions including 
memory and mood status. Receptors are mainly pres-
ent in the hippocampus[58,59]. Glutamine is important 
in energy metabolism of the brain and previous 
studies reported that a reduced level of glutamine is 
associated with brain diseases such as Alzheimer[60,61]. 
Increasing evidence shows that major depression dis-
order is associated with altered function of the major 
excitatory and inhibitory neurotransmitters such as 
glutamate and GABA[62,63]. The present study did not 
find correlations between depressive symptoms and 
the reduced Glx concentration and ratio to tCr.
These reduced MRS results found in the present 
pilot study in CD patients are not in accordance with 
the findings of previous research performed in other 
inflammatory diseases such as RA and SLE[11,64]. RA 
and SLE patients were shown to have increased cho-
line and myo-inisotol levels, indicating inflammation in 
the form of monocyte infiltration since this is a marker 
of cell membrane turnover[65,66]. In addition, in SLE 
patients only decreased NAA signals were reported, 
indicating neuronal loss[67-69], while an increased NAA 
ratio was found in our CD patient population. This con-
tradiction may be due to the fact that RA and SLE are 
systemic inflammatory diseases, but not comparable 
with the systemic inflammation in IBD.
CBF values can reveal changes in tissue perfu-
sion and are an indication for cerebral metabolism 
changes[70]. In the present study, significant higher CBF 
values were found in the patient population. Increased 
CBF is thought to be a compensatory mechanism in 
response to ischemia or injury, which could be the case 
in the CD patients due to inflammation[71,72]. Our find-
ings are in line with the results of Wang et al[31] who 
described in their cohort that SLE patients had higher 
CBF values compared with healthy controls. 
The volumetric results in this study extend on 
earlier findings in IBD patients. The reduced GM 
content of the superior frontal gyrus demonstrated in 
this study is in agreement with results presented by 
Agostini et al[73]. The superior frontal gyrus is involved 
the self-awareness, and important in processing infor-
mation[74,75]. It has been suggested that the observed 
decrease in local GM volume could have many causes, 
including a decrease in cell size, neural or glial cell 
apoptosis or changes in blood flow[72]. It is not clear 
whether this local volume reduction is directly linked to 
systemic inflammation, but it may represent the ana-
tomical substrate for the development of cognitive and 
emotional disturbances[73,76]. Similar significant positive 
correlations have been found between the GM volume 
in aging and measures of short-term memory[77].
Besides MRI findings, neuropsychological findings 
were assessed in this study. Previously, no evidence 
has been obtained on the association of the intrinsic 
disease process and cognitive dysfunction in IBD 
patients. It is probable that concurrent mood disor-
ders, in particular depression, affect the cognitive 
performance of IBD patients in memory and execu-
tive functioning tasks[55]. This may be the case in 
the current cohort, since depressive symptoms were 
correlated with reduced neuropsychological scores 
in the three different domains: cognitive functioning, 
memory and executive functioning. However, Berrill 
et al[78] suggested that intellectual deficits existed 
in IBD patients compared to controls and remained 
significant after the correction for educational level 
and mood disorders.
Previous studies have shown a link between systemic 
inflammation and reduced brain volumes, possibly 
resulting in cognitive deficits. Zonis et al[79] suggested 
that chronic intestinal inflammation alters hippocampal 
neurogenesis and thus might underlie the behavioural 
manifestations in patients with IBD. In another study, 
SLE patients with cognitive deficits appeared to have 
reduced temporal lobe structures (hippocampus and 
amgydala) compared to SLE patients without cognitive 
1025 February 14, 2017|Volume 23|Issue 6|WJG|www.wjgnet.com
Figure 3  FMRIB Software Library voxel based morphometry analysis. Voxel based morphometry results shown on MNI152 standard space. The red colour 
indicates the voxels with significantly reduced grey matter volume in CD patients compared with healthy controls (with a P-value < 0.05, corrected for multiple 
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deficits[80]. In the present study, we did not find these 
correlations.
Some limitations of this study need to be revealed. 
Although this study is an exploratory study, the popu-
lation size was limited. In this pilot study we have com-
pared the most extreme cases; quiescent CD patients 
with fatigue vs healthy controls without fatigue. In this 
design, we have found significant differences between 
the groups and now further research is required. In 
addition, the significant difference in the fatigue score 
between patients and controls is not a finding of the 
study, but part of the design. As a consequence, it 
cannot be definitely concluded whether the differences 
in MRI measures are caused by CD per se or represent 
only patients with combined CD and fatigue. However, 
fatigue is a subjective measurement and was evaluated 
as such. It is hard to draw major conclusions from 
these questionnaires, since some healthy controls 
reported a high fatigue score as well due to other cir-
cumstances than IBD. In some MRI analyses, subjects 
got excluded due to the quality of the data. MRS data 
with high Cramer-Rao lower bounds, suggesting unreli-
able metabolite quantification, were excluded from 
data analysis. This could have been influenced by the 
patients’ motion or bad shimming.
In conclusion, our findings support the hypothesis 
that systemic inflammation influences the brain and 
effects cognitive functioning and mood. This is a first 
step in the gathering of data and understanding of 
brain involvement in CD patients. This study implies 
that for a health professional, it is important to focus 
in CD patients not only on symptoms related to the 
gastrointestinal tract, but also on the effects of inflam-
mation on the brain. Understanding these affects in 
CD patients may help health professionals to set up 
interventions to maintain CD remission by the use of 




Both active and quiescent Crohn’s disease (CD) is a chronic inflammatory 
status in which levels of circulating inflammatory cytokines, such as tumour 
necrosis factor-α are reported in the body. These cytokines may play a role in 
driving inflammation in the brain by activating microglia and the recruitment of 
monocytes.
Research frontiers
Metabolic and cerebral perfusion changes have been found in the brain of 
patients with other systemic diseases including rheumatoid arthritis, systemic 
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 COMMENTS
1The global cognitive functioning domain includes the Minimal Mental 
State Examination; 2The memory domain includes the Wechsler Adult 
Intelligence Scale and the revised Wechsler Memory Scale; 3The executive 
functioning domain includes the Word Fluency Test, Stroop-Color-Word 
test and Trail Making Test. CD: Crohn’s disease.
Table 5  Z-scores of the different domains of cognitive 
functioning 
CD patients
(n  = 20)
Controls
(n  = 17)
P  value
Global cognitive functioning1, mean 
± SD
28.9 (1.6) 29.7 (0.5) 0.870
Memory2, mean ± SD 1.1 (2.9) 1.3 (2.3) 0.007
Executive functioning3, mean ± SD 2.5 (7.7) 2.9 (4.2) 0.020
Table 4  Mental status
CD patients
(n  = 20)
Controls
(n  = 17)
P  value
Global cognitive functioning
MMSE (total score), mean ± SD 28.9 (1.62) 29.65 (0.49) 0.87
Memory
Verbal
WMS memory quotient, mean ± SD3 109.2 (10.5) 115.7 (8.7) 0.72
Non verbal
WMS visual reproduction (total 
score), mean ± SD3
11.6 (2.7) 12.9 (2.2) 0.75
WAIS-R Digit Span forward, mean ± 
SD
5.4 (1.0) 6.5 (1.3) 0.15
WAIS-R Digit Span backward, mean 
± SD
4.5 (1.0) 5.2 (0.9) 0.15
Executive functioning
WFT, mean ± SD1
No. of good answers 42.7 (7.8) 48.2 (9.8) 0.29
No. of perseverative errors 0.28 (0.5) 0.47 (0.8) 0.58
Stroop Color-Word test, mean ± SD
Stroop 1 time (s) 43.9 (7.2) 39.2 (8.6) 0.41
Stroop 1 No. of errors 0.2 (0.4) 0.1 (0.3) 0.98
Stroop 2 time (s) 56.6 (8.3) 53.8 (6.9) 0.62
Stroop 2 No. of errors 0.3 (0.8) 0 (0.0) 0.21
Stroop 3 time (s) 88.3 (14.7) 76.6 (8.8) 0.22
Stroop 3 No. of errors 0.6 (1.5) 0.13 (0.3) 0.20
Stroop interference index 50.1 (7.8) 56.1 (5.5) 0.06
TMT, mean ± SD
Part A time (s) 30.3 (11.8) 22.1 (8.5) 0.08
Part A no. of errors 0.1 (0.2) 0.1 (0.2) 0.56
Part B time (s) 61.8 (29.2) 50.1 (17.4) 0.72
Part B no. of errors 0.1 (0.2) 0.2 (0.5) 0.41
WAIS-R Digit Symbol, mean ± SD2
Total score 59.7 (8.4) 71.0 (6.2) 0.06
No. of errors 0 (0.0) 0.1 (0.3) 0.63
Digit cancellation test, mean ± SD4
Total score 436.2 (88.1) 498.6 (82.9) 0.16
No. of good answers (%) 57.3 (29.5) 78.9 (20.9) 0.16
HADS, mean ± SD 13.1 (7.3) 4.8 (2.9) < 0.001
Anxiety 7.5 (3.8) 3.7 (2.7)    0.002
Depression 6.1 (4.0) 0.9 (1.1) < 0.001
SF-36
Physical functioning 72.9 ± 20.2 96.6 ± 3.4 < 0.001
Social functioning 52.0 ± 29.0 90.7 ± 9.8 < 0.001
Role physical problem 71.3 ± 37.4   2.9 ± 8.3 < 0.001
Role emotional problem 40.4 ± 46.1   2.0 ± 8.1    0.002
Bodily pain 35.3 ± 20.7     5.6 ± 12.6 < 0.001
General health perception 65.8 ± 18.8   82.0 ± 15.2 < 0.001
Mental health 63.6 ± 16.0   80.4 ± 10.9    0.001
Vitality 30.1 ± 18.3   72.9 ± 14.3 < 0.001
1Missing in 2 CD patients; 2Missing 1 CD patient and 1 healthy control; 
3Missing in 2 healthy controls; 4Missing in 5 patients and 3 healthy 
controls. To correct for multiple testing, the level of significance was set 
at P < 0.006 for the SF-36 score. MMSE: Mini Mental State Examination; 
WMS: Wechsler Memory Scale; WAIS-R: Wechsler Adult Intelligence 
Scale-Revised; WFT: Word Fluency Test; TMT: Trial Making test; HADS: 
Hospital Anxiety Depression Scale; CD: Crohn’s disease.
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sclerosis and systemic lupus erythematosus. In addition, previous studies found 
an association with fatigue and metabolic brain changes. Thus it is of interest, 
whether systemic inflammation and fatigue complaints influence the brain in CD 
patients as well.
Innovations and breakthroughs
The present data support the hypothesis that systemic inflammation influences 
the brain and affects cognitive functioning and mood status in quiescent CD 
patients with fatigue. This is a first step in understanding brain involvement in 
CD patients. 
Applications
This study implies that for a health professional, it is important to focus in CD 
patients also on the effects of inflammation on the brain. Understanding these 
affects in CD patients may help health professionals to set up interventions to 
maintain CD remission by the use of medication and to improve mood status 
and QoL by e.g., psychosocial interventions.
Peer-review
Since this is an exploratory study, the authors have compared the most extreme 
cases; quiescent CD patients with fatigue vs healthy controls without fatigue. In 
this design, the authors have found significant differences between the groups 
and now further research is required.
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